IL10 and hepatocellular carcinoma: For example, studies in patients with HCC reveal that two distinct populations (HLA-DRhigh and HLA-DRlow IL-10+) of monocytes/MΦ exist within different regions of the tumor, which modulate T cell activation via different mechanisms [4,5].